[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

JO3421B1 - طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية - Google Patents

طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Info

Publication number
JO3421B1
JO3421B1 JOP/2012/0162A JOP20120162A JO3421B1 JO 3421 B1 JO3421 B1 JO 3421B1 JO P20120162 A JOP20120162 A JO P20120162A JO 3421 B1 JO3421 B1 JO 3421B1
Authority
JO
Jordan
Prior art keywords
sub
indan
piperazine
trimethyl
chloro
Prior art date
Application number
JOP/2012/0162A
Other languages
English (en)
Inventor
Bruun Lone
Holm Rene
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Application granted granted Critical
Publication of JO3421B1 publication Critical patent/JO3421B1/ar

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4515Non condensed piperidines, e.g. piperocaine having a butyrophenone group in position 1, e.g. haloperidol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/55131,4-Benzodiazepines, e.g. diazepam or clozapine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

يتعلق الاختراع الحالي ب 4-((1R،3S)-6-كلورو-3-فينيل-إندان-1-يل)-1،2،2-تراي ميثيل –ببرازين وأملاح منه ذات نشاط عند مستقبلات الدوبامين D<sub>1</sub> وD<sub>2</sub> إلى جانب مستقبل السيروتونين 5HT<sub>2</sub> لعلاج الأمراض في الجهاز العصبي المركزي في نظام جرعات مرة واحدة أسبوعيا
JOP/2012/0162A 2011-06-20 2012-06-19 طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية JO3421B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DKPA201100465 2011-06-20

Publications (1)

Publication Number Publication Date
JO3421B1 true JO3421B1 (ar) 2019-10-20

Family

ID=58794324

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2012/0162A JO3421B1 (ar) 2011-06-20 2012-06-19 طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية

Country Status (22)

Country Link
US (1) US9610287B2 (ar)
EP (1) EP2720698B1 (ar)
JP (1) JP6140151B2 (ar)
KR (1) KR101900989B1 (ar)
CN (1) CN103608015A (ar)
AU (1) AU2012274150B2 (ar)
BR (1) BR112013032178A2 (ar)
CA (1) CA2838055C (ar)
DK (1) DK2720698T3 (ar)
ES (1) ES2694298T3 (ar)
HR (1) HRP20181684T1 (ar)
IL (1) IL230060A (ar)
JO (1) JO3421B1 (ar)
LT (1) LT2720698T (ar)
MX (1) MX349754B (ar)
PL (1) PL2720698T3 (ar)
RS (1) RS57944B1 (ar)
RU (1) RU2613177C2 (ar)
SI (1) SI2720698T1 (ar)
TW (1) TWI552751B (ar)
WO (1) WO2012175531A1 (ar)
ZA (1) ZA201309617B (ar)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7402400B2 (en) 2001-07-03 2008-07-22 Regents Of The University Of California Mammalian sweet taste receptors
ES2307542T3 (es) 1999-11-17 2008-12-01 Mendel Biotechnology, Inc. Genes resistentes al estres medioambiental.
US6458538B1 (en) 1999-12-14 2002-10-01 Ptc Therapeutics, Inc. Methods of assaying for compounds that inhibit premature translation termination and nonsense-mediated RNA decay
TW201006846A (en) 2000-03-07 2010-02-16 Senomyx Inc T1R taste receptor and genes encidung same
EP2410060A1 (en) 2000-08-22 2012-01-25 Mendel Biotechnology, Inc. Genes for modifying plant traits IV
US7045283B2 (en) 2000-10-18 2006-05-16 The Regents Of The University Of California Methods of high-throughput screening for internalizing antibodies
US7883856B2 (en) 2001-04-05 2011-02-08 Senomyx Inc. Identification of bitter ligands that specifically activate human T2R receptors and related assays for identifying human bitter taste modulators
CN100489102C (zh) 2001-06-26 2009-05-20 塞诺米克斯公司 T1r异源寡聚的味觉受体和表达所述受体的细胞系及其在鉴定味觉化合物中的用途
US7871619B2 (en) 2001-11-30 2011-01-18 Chemocentryx, Inc. Compositions and methods for detecting and treating diseases and conditions related to chemokine receptors
AU2003304411A1 (en) 2002-08-01 2005-03-07 The Regents Of The University Of California Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
AU2003243151A1 (en) 2002-08-16 2004-03-03 Agensys, Inc. Nucleic acid and corresponding protein entitled 251p5g2 useful in treatment and detection of cancer
BR0314389A (pt) 2002-09-18 2005-07-12 Mendel Biotechnology Inc Polinucleotìdeos e polipeptìdeos em plantas
ES2384622T3 (es) 2003-05-30 2012-07-10 Agensys, Inc. Variantes del antígeno de células madre de próstata (PSCA) y subsecuencias de las mismas
EP2369348A1 (en) 2003-11-07 2011-09-28 Ciphergen Biosystems, Inc. Biomarkers for Alzheimer's disease
EP2322637B1 (en) 2003-12-24 2016-05-18 Novo Nordisk A/S Transgenic mouse comprising a polynucleotide encoding human or humanized C5AR
ES2671522T3 (es) 2004-04-02 2018-06-06 The Regents Of The University Of California Métodos y composiciones para tratar y prevenir una enfermedad asociada con la integrina alfa V beta 5
US7939251B2 (en) 2004-05-06 2011-05-10 Roche Molecular Systems, Inc. SENP1 as a marker for cancer
NZ551627A (en) 2004-05-28 2010-02-26 Agensys Inc Antibodies and related molecules that bind to PSCA proteins
WO2006002262A2 (en) 2004-06-21 2006-01-05 The Board Of Trustees Of The Leland Stanford Junior University Genes and pathways differentially expressed in bipolar disorder and/or major depressive disorder
US7850960B2 (en) 2004-12-30 2010-12-14 University Of Washington Methods for regulation of stem cells
EP1850866A4 (en) 2005-01-27 2009-07-08 Univ California MONOCLONAL THERAPEUTIC ANTIBODIES FOR THE NEUTRALIZATION OF BOTULIN NEUROTOXINES
RU2413735C2 (ru) 2005-03-31 2011-03-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками 161p2f10b
ES2686093T3 (es) 2005-07-19 2018-10-16 Stemgen S.P.A. Inhibición del potencial tumorigénico de células madre tumorales por BMP-4
MX2007015931A (es) 2005-10-20 2008-04-22 Senomyx Inc Receptores de sabor dulce-umami y umami-dulce humanos quimericos.
AU2006311661B2 (en) 2005-11-07 2011-05-26 The Scripps Research Institute Compositions and methods for controlling tissue factor signaling specificity
JP5366554B2 (ja) 2005-11-12 2013-12-11 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー うつを診断および処置するためのfgf2関連方法
CN103301475B (zh) 2005-12-28 2016-08-03 斯克里普斯研究所 药物组合物和表达载体以及调节基因表达的方法和核酸分子的应用
US20100278821A1 (en) 2006-03-21 2010-11-04 The Regents Of The University Of California N-cadherin: target for cancer diagnosis and therapy
WO2007109347A2 (en) 2006-03-21 2007-09-27 The Regents Of The University Of California N-cadherin and ly6 e: targets for cancer diagnosis and therapy
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
EP2423332A1 (en) 2006-08-25 2012-02-29 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
EP2680000A1 (en) 2006-09-06 2014-01-01 The Regents of the University of California Molecular diagnosis and classification of malignant melanoma
EP2095100B1 (en) 2006-11-22 2016-09-21 President and Fellows of Harvard College Method of operating a nanowire field effect transistor sensor
EP2166843A4 (en) 2007-06-01 2010-08-11 Univ Princeton TREATMENT OF VIRUS INFECTIONS BY MODULATION OF HOST CELL METABOLISMS
AU2008286361B2 (en) 2007-08-13 2013-09-26 Takeda Pharmaceutical Company Limited IVIG modulation of chemokines for treatment of multiple sclerosis, Alzheimer's disease, and Parkinson's disease
RO128637A2 (ro) 2007-08-21 2013-07-30 Senomyx, Inc. Identificarea receptorilor t2r umani care răspund la compuşii amari care extrag gustul amar din compoziţii, şi utilizarea acestora în analize pentru a identifica compuşii care inhibă () gustul amar în compoziţii şi utilizarea acestora
AU2008308509B2 (en) 2007-10-04 2014-10-23 Zymogenetics, Inc. B7 family member zB7H6 and related compositions and methods
CA2703165A1 (en) 2007-10-22 2009-04-30 The Regents Of The University Of California Biomarkers for prenatal diagnosis of congenital cytomegalovirus
EP2217716A4 (en) 2007-11-09 2011-02-09 Salk Inst For Biological Studi USE OF TAM RECEPTOR INHIBITORS AS ANTIMICROBIAL AGENTS
MX2010010165A (es) 2008-03-17 2010-11-25 Scripps Research Inst Procedimientos quimicos y geneticos combinados para generacion de celulas madre pluripotentes inducidas.
WO2009132020A2 (en) 2008-04-21 2009-10-29 The Regents Of The University Of California Selective high-affinity polydentate ligands and methods of making such
EP2942357A1 (en) 2008-08-04 2015-11-11 Glen N. Barber Sting (stimulator of inteferon genes), a regulator of innate immune responses
CA2738019A1 (en) 2008-09-23 2010-04-08 President And Fellows Of Harvard College Sirt4 and uses thereof
EP3260123A1 (en) 2008-11-06 2017-12-27 University of Miami Role of soluble upar in the pathogenesis of proteinuric kidney disease
US8735082B2 (en) 2008-11-10 2014-05-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gene signature for predicting prognosis of patients with solid tumors
WO2010065721A1 (en) 2008-12-03 2010-06-10 The Scripps Research Institute Stem cell cultures
US8906677B2 (en) 2008-12-17 2014-12-09 The Scripps Research Institute Generation and maintenance of stem cells
AU2010241947B2 (en) 2009-03-27 2014-01-16 Gojo Industries, Inc. Compositions and methods for screening and using compounds antagonizing spore-surface interactions
EP2456460A4 (en) 2009-07-24 2013-02-20 Univ California METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING INEGRINE V ASSOCIATED DISEASES
US8383360B2 (en) 2009-08-14 2013-02-26 The Regents Of The University Of California Methods of diagnosing and treating autism
WO2011022638A1 (en) 2009-08-20 2011-02-24 Transposagen Biopharmaceuticals, Inc. Trp inhibitors and uses thereof
US9297796B2 (en) 2009-09-24 2016-03-29 President And Fellows Of Harvard College Bent nanowires and related probing of species
ES2365343B1 (es) 2009-11-19 2012-07-10 Fundación Centro Nacional De Investigaciones Cardiovasculares Carlos Iii Uso de cd98 como marcador de receptividad endometrial.
WO2011094759A2 (en) 2010-02-01 2011-08-04 The Regents Of The University Of California Novel diagnostic and therapeutic targets associated with or regulated by n-cadherin expression and/or epithelial to mesenchymal transition (emt) in prostate cancer and other malignancies
WO2012052391A1 (en) 2010-10-19 2012-04-26 Glaxo Group Limited Polypeptide with jmjd3 catalytic activity
WO2012109495A1 (en) 2011-02-09 2012-08-16 Metabolic Solutions Development Company, Llc Cellular targets of thiazolidinediones
WO2012119989A2 (en) 2011-03-04 2012-09-13 Oryzon Genomics, S.A. Methods and antibodies for the diagnosis and treatment of cancer
US20120301904A1 (en) 2011-04-26 2012-11-29 Prosetta Antiviral, Inc Multiprotein assemblies
WO2013138463A1 (en) 2012-03-14 2013-09-19 University Of Central Florida Research Foundation, Inc. Neurofibromatoses therapeutic agents and screening for same
US20150087628A1 (en) 2012-04-10 2015-03-26 The Regents Of The University Of California Compositions and methods for treating cancer
KR20150023287A (ko) 2012-04-24 2015-03-05 더 유니버시티 오브 마이애미 침습성 및 다중약물 내성 병원체에 대한 퍼포린 2 방어
EP3184121A3 (en) 2012-07-25 2017-09-27 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
US9750705B2 (en) 2012-08-31 2017-09-05 The Regents Of The University Of California Agents useful for treating obesity, diabetes and related disorders
AU2013204200B2 (en) 2012-10-11 2016-10-20 Brandeis University Treatment of amyotrophic lateral sclerosis
US20140120116A1 (en) 2012-10-26 2014-05-01 The Chinese University Of Hong Kong Treatment of cancer using smad3 inhibitor
WO2014124339A2 (en) 2013-02-07 2014-08-14 The Regents Of The University Of California Use of translational profiling to identify target molecules for therapeutic treatment
WO2014144844A1 (en) 2013-03-15 2014-09-18 The Board Of Trustees Of The Leland Stanford Junior University tRNA DERIVED SMALL RNAs (tsRNAs) INVOLVED IN CELL VIABILITY
EP3079475B1 (en) 2013-12-11 2020-10-07 Sloan-kettering Institute For Cancer Research Glucocorticoid inhibitors for treatment of prostate cancer
WO2015089327A1 (en) 2013-12-11 2015-06-18 Biogen Idec Ma Inc. Biaryl compounds useful for the treatment of human diseases in oncology, neurology and immunology
WO2015136509A2 (en) 2014-03-14 2015-09-17 Genesis Theranostix Korlatolt Felelossegu Tarsasag Diagnostic and therapeutic targets for preeclampsia and closely related complications of pregnancy
WO2016195982A2 (en) 2015-06-01 2016-12-08 The Penn State Research Foundation Hepatitis b virus capsid assembly
US10782304B2 (en) 2015-06-24 2020-09-22 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for detecting protein-protein interactions
WO2018036503A1 (en) 2016-08-25 2018-03-01 The Chinese University Of Hong Kong Fecal bacterial markers for colorectal cancer
EP3555077B1 (en) 2016-12-15 2023-04-19 The Regents of The University of California Compositions and methods for treating cancer
EP3601326A4 (en) 2017-03-20 2020-12-16 The Broad Institute, Inc. COMPOUNDS AND METHODS OF REGULATING INSULIN SECRETION
WO2020087107A1 (en) 2018-10-31 2020-05-07 The University Of Sydney Compositions and methods for treating viral infections
WO2020097261A1 (en) 2018-11-06 2020-05-14 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services New compositions and methods for treating beta-globinopathies
WO2023081167A2 (en) 2021-11-02 2023-05-11 The Regents Of The University Of California P-selectin mutants and modulation of integrin-mediated signaling
WO2023146807A1 (en) 2022-01-25 2023-08-03 The Regents Of The University Of California Vegf mutants and modulation of integrin-mediated signaling
WO2024197185A1 (en) 2023-03-21 2024-09-26 The Broad Institute, Inc. Methods and compositions for dissecting organelle physiology

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK55192D0 (da) 1992-04-28 1992-04-28 Lundbeck & Co As H 1-piperazino-1,2-dihydroindenderivater
CA2536144C (en) 2003-08-18 2010-09-14 H. Lundbeck A/S Succinate and malonate salt of trans-4-(ir,3s)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
BRPI0510074A (pt) 2004-04-22 2007-10-16 Boehringer Ingelheim Int composições farmacêuticas para o tratamento de distúrbios sexuais ii
EP1909689A4 (en) 2005-07-18 2011-11-16 Univ Pennsylvania IMPLANTS CONTAINING A MEDICAMENT AND METHOD OF USE
EA018927B1 (ru) * 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
BRPI0919165A2 (pt) * 2008-10-03 2015-12-08 Lundbeck & Co As H composição farmacêutica,e, uso de um composto
BRPI1011453A2 (pt) 2009-06-24 2016-03-15 Msd Oss Bv formulacao, forma de dosagem de um medicamento, e, sal de hemipamoato de asenapina

Also Published As

Publication number Publication date
JP6140151B2 (ja) 2017-05-31
WO2012175531A1 (en) 2012-12-27
EP2720698B1 (en) 2018-10-03
HRP20181684T1 (hr) 2018-12-14
US9610287B2 (en) 2017-04-04
SI2720698T1 (sl) 2018-12-31
DK2720698T3 (en) 2018-11-26
AU2012274150A1 (en) 2014-01-09
KR20140033419A (ko) 2014-03-18
EP2720698A1 (en) 2014-04-23
RU2613177C2 (ru) 2017-03-15
PL2720698T3 (pl) 2019-01-31
AU2012274150B2 (en) 2016-10-06
CN103608015A (zh) 2014-02-26
LT2720698T (lt) 2018-11-12
MX349754B (es) 2017-08-11
RU2014101482A (ru) 2015-07-27
MX2013014978A (es) 2014-04-10
CA2838055C (en) 2021-01-26
KR101900989B1 (ko) 2018-09-20
RS57944B1 (sr) 2019-01-31
TWI552751B (zh) 2016-10-11
CA2838055A1 (en) 2012-12-27
ES2694298T3 (es) 2018-12-19
US20140194409A1 (en) 2014-07-10
BR112013032178A2 (pt) 2016-12-20
TW201306840A (zh) 2013-02-16
ZA201309617B (en) 2015-04-29
IL230060A (en) 2017-10-31
JP2014517050A (ja) 2014-07-17

Similar Documents

Publication Publication Date Title
JO3421B1 (ar) طريقة لإعطاء 1-((1ار.3س)-6-كلورو-3-فينيل-اندان-1-ايل)-1.2.2-ترايميثيل- بيبيرازين واملاجها لمعالجة انفصام الشخصية
MY174888A (en) Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
IN2014DN09434A (ar)
ECSP13012871A (es) Moduladores del receptor de glucagón
MD4538C1 (ro) 1-Piperazino-3-fenil-indani deuteraţi pentru tratamentul schizofreniei
UA107334C2 (ru) Производные аминоэфиров алкалоидов и их лекарственные композиции
CL2013003042A1 (es) Compuestos derivados metilamina de biciclos sustituidos, moduladores de receptores de esfingosin-1- fosfato; composicion farmaceutica; y un metodo de tratamiento para tratar enfermedades oculares, degeneracion macular, retinopatia, entre otros
PH12014502750A1 (en) Heteroaromatic methyl cyclic amine derivative
PH12014501195A1 (en) Novel 2h-indazoles as ep2, receptor antagonists
MX2015013328A (es) Uso de antagonistas del receptor de ep4 en el tratamiento de enfermedad de cartilago.
EA201490938A1 (ru) Производные спиротиенопиранпиперидина в качестве антагонистов рецептора orl-1 для применения для лечения алкогольной зависимости и злоупотребления алкоголем
WO2013048949A3 (en) Selective nr2b antagonists
MX2014000855A (es) Moduladores receptores de glucagon de quinolinilo.
EA201391348A1 (ru) КОМБИНАЦИИ АКТИВАТОРОВ АЛЬФА-7 НИКОТИНОВОГО АЦЕТИЛХОЛИНОВОГО РЕЦЕПТОРА И АНТАГОНИСТОВ mGluR5, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ПРИМЕНЕНИЯ ПРИ ВЫЗВАННОЙ ДОПАМИНОМ ДИСКИНЕЗИИ, СВЯЗАННОЙ С БОЛЕЗНЬЮ ПАРКИНСОНА
TN2013000503A1 (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
MY166773A (en) Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia
UA106839C2 (uk) Модулятори глюкагон рецептора